Max-Planck-Gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

U3 Pharma Gmbh

Amgen Inc.

U3 Pharma Ag

Esther Zwick-Wallasch

Mike Rothe

Thore Hettmann

Axel Ullrich

Orit Foord

Eric Borges

Henrik Daub

Jens Ruhe

Peter Wirtz

Kerstin Selle

Norbert Prezel

Kerstin Dehne

Luis A Pardo

David Gómez-Varela

Hendrik Knötgen

Walter Stühmer

Norbert Prenzel

Jens Niewöhner

The present invention refers to antibodies, particularly to monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.

AXL antibodies

Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.

Heparin-binding epidermal growth factor-like growth factor binding proteins

The present invention relates to a particularly advantageous antibody, antibody fragment or derivative thereof, which specifically binds to/interacts with at least one epitope of the extracellular or intracellular domain or the mammalian EAG1 ion channel and to nucleic acid molecules encoding these anti-EAG1 antibodies, antibody fragments or derivatives and to vectors comprising such nucleic acid molecules. The invention additionally relates to methods for the preparation of such anti-EAG1 antibodies, antibody fragments or derivatives thereof, pharmaceutical compositions comprising these antibodies, antibody fragments or derivatives, and methods of using the antibodies, antibody fragments or derivatives or the compositions for a variety of purposes, such as diagnosing disease, treating disease, assessing for the presence of EAG1-expressing cells, or blocking EAG1 function in cells.

Antibodies directed to the mammalian EAG1 ion channel protein

The present invention relates to agents and methods for growth-factor receptor activation by modulating the G-protein mediated signal transduction pathway.

EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF

Growing community of inventors

Gauting, Germany

Esther Zwick-Wallasch